HearingNCT07254442
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
An observational study of Hearing and COVID - 19, run by Zonguldak Bulent Ecevit University at 1 site in Turkey (Türkiye).
Trial summary
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Hearing, COVID - 19, Ototoxicity
- What is being tested?
- Hearing tests
- How many people
- 90 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Dec 2021to 1 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: 1. Those who have had COVID-19 and are taking medication 2. Those who have had COVID-19 and are not taking medication 3. Healthy individuals who have not had COVID-19
Who may be able to join
- Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19
Who cannot join
- Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care
Trial locations and contacts
1 site in 1 country.
About this study
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
Read the detailed description
This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.
- Conditions
- Hearing, COVID - 19, Ototoxicity
- Being tested
- Hearing tests
- Medical subject headings
- COVID-19, Ototoxicity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hearing testsDiagnostic test
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Group that has not had Covid-19 Receives: Diagnostic Test: Hearing tests | |
| Medication Group | The group that had Covid-19 and used medication Receives: Diagnostic Test: Hearing tests | |
| Non-medication group | The group that had Covid-19 and did not use medication Receives: Diagnostic Test: Hearing tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pure tone and high frequency hearing thresholds
Measured: December, 2021-February 2022
Transient evoked otoacoustic emissions - Signal/noise ratio
Measured: December, 2021-February 2022
Distortion product otoacoustic emissions- signal/noise ratio
Measured: December, 2021-February 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2025
- Study start1 Dec 2021
- Primary completion1 Feb 2022
- Study completion1 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HearingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zonguldak Bulent Ecevit University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Azize Arzu KÖROĞLU KOÇYİĞİT, Zonguldak Bulent Ecevit University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07254442
- Sponsor's protocol ID
- 2021/61-18
- Other IDs
- 1919B012102481
- Status last verified
- Nov 2025
- First submitted
- 26 Sep 2025
- Last updated
- 28 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
- ClinicalTrials.gov ID
- NCT07254442
- Acronym / sponsor ID
- 2021/61-18
- Conditions
- Hearing, COVID - 19, Ototoxicity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Zonguldak Bulent Ecevit UniversityUniversity, hospital or other
- Study start
- 1 Dec 2021 (actual)
- Primary completion
- 1 Feb 2022 (actual)
- Study completion
- 1 Mar 2022 (actual)
- First posted
- 28 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
Detailed description
This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control group | – | Diagnostic Test: Hearing testsGroup that has not had Covid-19 |
| Medication Group | – | Diagnostic Test: Hearing testsThe group that had Covid-19 and used medication |
| Non-medication group | – | Diagnostic Test: Hearing testsThe group that had Covid-19 and did not use medication |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- 1. Those who have had COVID-19 and are taking medication 2. Those who have had COVID-19 and are not taking medication 3. Healthy individuals who have not had COVID-19
Key inclusion criteria (1 listed)
- Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19
Key exclusion criteria (1 listed)
- Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hearing testsParticipants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated. | Diagnostic test | Control group, Medication Group, Non-medication group |
Primary outcome
Pure tone and high frequency hearing thresholds
Time frame: December, 2021-February 2022
Transient evoked otoacoustic emissions - Signal/noise ratio
Time frame: December, 2021-February 2022
Distortion product otoacoustic emissions- signal/noise ratio
Time frame: December, 2021-February 2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Hearing
RecruitingObservational study
Impact of Vestibular Function on Deaf Infants' Activities of Daily Living
Vestibular Dysfunction, Hearing Loss
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
Not yet recruiting
Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss
Hearing Loss, Bilateral
Not yet recruitingPhase 1/2
Acute Nicotine Gum and Auditory Brain Responses in Adults With Chronic Tinnitus
Tinnitus, Chronic Subjective Tinnitus
RecruitingObservational study
Natural History of Autosomal Dominant Hearing Loss
Hearing Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hearing and COVID - 19, run by Zonguldak Bulent Ecevit University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pure tone and high frequency hearing thresholds (time frame: December, 2021-February 2022). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025.